Quantcast

Latest tumor Stories

2014-02-20 12:15:21

St. Jude Children's Research Hospital--Washington University Pediatric Cancer Genome Project identifies the most common genetic alteration yet in the brain tumor ependymoma; results offer clues for fighting other cancers The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The research appears...

2014-02-19 16:23:43

St. Jude Children's Research Hospital -Washington University Pediatric Cancer Genome Project identifies the most common genetic alteration yet in the brain tumor ependymoma; results offer clues for fighting other cancers MEMPHIS, Tenn., Feb. 19, 2014 /PRNewswire-USNewswire/ -- The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that...

2014-02-19 12:44:47

Cancer cell spread to the sentinel node—the lymph node to which cancer cells are most likely to spread from a primary tumor—is a risk factor for melanoma death. According to a study published in this week's PLOS Medicine by Anja Ulmer, Christoph Klein and colleagues from the Universities of Tübingen and Regensburg, Germany, the prognosis of a patient largely depends on the number of disseminated cancer cells per million lymphocytes in the sentinel node. Even very low numbers were found...

2014-02-17 08:25:31

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Clinical Laboratory Services Market (Clinical Chemistry, Medical Microbiology & Cytology, Human & Tumor Genetics and Other Esoteric Tests) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 The report covers the global clinical laboratory services market based on the various categories of tests conducted by laboratories, including clinical chemistry,...

2014-02-14 08:26:33

Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb. 14, 2014 /PRNewswire/ -- MultiVir, a leader in gene therapies for cancer treatment, presented to the investment community at the Leerink Global Healthcare Conference. Highlights of the presentation included an overview of the development plans for the company's two lead products which are supported by strong pre-clinical and clinical data. MultiVir's adenoviral p53 (Ad-p53) and adenoviral interleukin 24...

2014-02-11 08:32:18

US and Japanese patents cover the Company's whole slide imaging and analysis platform, which simultaneously measures tumor, immune, and stromal cells, processes, and biomarkers on a single specimen PITTSBURGH, Feb. 11, 2014 /PRNewswire/ -- Cernostics, a diagnostics company delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that the United States Patent and Trademark Office has issued two patents, US Patent 8,114,615 and US Patent...

2014-02-04 11:57:02

Largest-ever study of 20-year survival among pediatric low-grade glioma patients highlights radiation's association with higher mortality The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults. However, children who received radiation as part of their treatment had significantly lower long-term...

2014-02-04 11:02:59

Presence of IDH1 mutation determines best treatment for malignant astrocytomas Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years. Now a new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Preliminary results of the study...

2014-01-30 23:22:28

This report from BCC Research focuses on circulating tumor cell testing and monitoring methods, and includes an overview on cancer, diagnostic strategies, and treatment technologies. Important trends in the field of cancer research and development are reviewed and sales forecasts by treatment and screening categories are provided from 2013 through 2018. Wellesley, MA (PRWEB) January 30, 2014 According to a new technical market research report Circulating Tumor Cell (CTC) Diagnostics:...

2014-01-30 12:28:48

International studies demonstrate importance of comprehensive tumor profiling for poor-prognosis cancer patients IRVING, Texas, Jan. 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present two tumor profiling studies at the 2014 Genitourinary Cancers Symposium held this week in San Francisco, Calif. Through use of the company's comprehensive tumor profiling service, Caris Molecular Intelligence,...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related